Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, John C. Riches et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 5
CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, Allison Winter et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 2